0001339970-26-000033
SEC filingOperating losses narrowed 27.5% to -$11.4M in Q1 2026, driven by reduced efzofitimod expenses following EFZO-FIT study completion, while cash used in operations improved to -$12.5M amid preclinical investments and funding needs for Phase 3.
General and administrative expenses encompass ongoing costs like accounting, legal services, patent maintenance, insurance, consultants, occupancy, IT, and depreciation, which remained stable in context. The company maintains responsibility for supplying drug product and supporting efzofitimod development activities, including for Japan partnerships. Lung function maintenance observed in EFZO-FIT via FVC at week 48 underscores the study's positive outcomes enabling this transition.
Looking forward, additional capital will be required through equity offerings, debt, grants, collaborations, or licensing to sustain operations and Phase 3 execution. Uncertainty around future partnerships adds variability to development plans and capital needs, emphasizing the importance of these funding avenues for continued progress.